Raymond James Starts Nivalis Therapeutics (NVLS) at Outperform
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Raymond James initiated coverage on Nivalis Therapeutics (NASDAQ: NVLS) with an Outperform rating and a price target of $20.00.
Shares of Nivalis Therapeutics closed at $7.77 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Starts AMAG Pharmaceuticals (AMAG) at Buy
- UPDATE: MKM Partners Upgrades Masco (MAS) to Buy
- Asbury Automotive Group (ABG) PT Lowered to $55 at Jefferies
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Related EntitiesRaymond James
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!